Spiriva Respimat
Novartis and Boehringer Ingelheim Launch Direct-to-Consumer Drug Sales, Bypassing Middlemen
Boehringer Ingelheim; Novartis; Direct-to-consumer (DTC); Pharmaceutical sales; Middlemen; Drug pricing; Patient access; Cosentyx; Spiriva Respimat; PhRMA